Overview

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Subjects and Heart Failure Patients

Status:
Terminated
Trial end date:
2019-04-18
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy subjects, who received AMG 986 by constant intravenous (IV) infusion or oral (PO) administration and of ascending multiple PO doses of AMG 986 in heart failure patients (Part C).
Phase:
Phase 1
Details
Lead Sponsor:
Amgen